- Home
- BRT vs TARA Comparison
BRT vs TARA Comparison
Compare BRT & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | TARA |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.3M | 268.5M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BRT | TARA |
|---|---|---|
| Price | $14.20 | $5.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $19.75 | ★ $21.67 |
| AVG Volume (30 Days) | 85.2K | ★ 586.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | $2,948,000.00 |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.18 | $2.77 |
| 52 Week High | $16.69 | $7.82 |
Technical Indicators
Market Signals| Indicator | BRT | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 45.62 |
| Support Level | $13.18 | $4.92 |
| Resistance Level | $15.11 | $5.44 |
| Average True Range (ATR) | 0.33 | 0.27 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 89.34 | 49.28 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).